Quincy Olivari remains an unrestricted NBA free agent following his recent stint with the Portland Trail Blazers in the NBA Summer League. The 25-year-old guard, who previously drew attention as a preseason standout for the Los Angeles Lakers, is currently seeking a roster spot or a training camp invitation for the upcoming season after posting averages of 9.3 points, 3.7 rebounds, and 3.0 assists over three games in Las Vegas.
Evaluating Olivari’s Summer League Performance
Olivari’s transition to the Trail Blazers’ summer roster provided a critical window for front offices to evaluate his production against professional-caliber competition. According to league data, he maintained a 37.5% success rate from beyond the three-point arc while contributing 1.3 steals per contest. This defensive activity, paired with his perimeter shooting efficiency, serves as the primary resume point for teams looking to fill depth chart vacancies before training camp begins.
Did you know?
The Path from Preseason Standout to Free Agent
Before his appearance in Las Vegas, Olivari gained recognition during the 2024 preseason while wearing a Los Angeles Lakers jersey. A notable moment occurred during an October 18, 2024, game at the Chase Center, where Olivari was matched up against Golden State Warriors guard De’Anthony Melton.
Strategic Considerations for NBA Roster Construction
Unlike established veterans, free agents like Olivari must demonstrate immediate utility in specific areas—such as floor spacing or perimeter defense—to displace incumbents on a 15-man roster.
Frequently Asked Questions
- Is Quincy Olivari currently signed with an NBA team? No, as of July 15, Olivari is an unrestricted free agent available to sign with any team.
- What were Olivari’s stats in the NBA Summer League? He averaged 9.3 points, 3.7 rebounds, and 3.0 assists per game.
- What is an Exhibit 10 contract?
Are you tracking the latest roster moves for the upcoming NBA season? Subscribe to our newsletter for daily updates on free agency, trade rumors, and scouting reports.
Worth a look
- Serie A Title Race & De Zerbi: Italy’s Tactical Confusion Explained
- Swedish Players and Captains Lead Europe to Solheim Cup Victory
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)